** Shares of telehealth company Mangoceuticals , also known as MangoRx, rise 2.1% to $3.94 premarket
** Company says it has initiated a review process to evaluate potential strategic alternatives, including but not limited to potential mergers, acquisitions, divestitures and other transactions
** MGRX has not established a timeline for completion of the review process
** Earlier this week, Eli Lilly sued three medical spas and online vendors, including MangoRx, for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss drug Zepbound
** The lawsuit came after MangoRx launched its own brand called "Trim" — a compounded, oral dissolvable tirzepatide tablet
** Up to last close, stock down 41.5% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。